AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting

• AstraZeneca Plc (NASDAQ: AZN) has reported preliminary results from the SAVANNAH Phase 2 trial of Tagrisso (osimertinib) plus savolitinib in epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, whose disease progressed on Tagrisso.

• Tagrisso plus savolitinib demonstrated an objective response rate (ORR) of 49%.

• The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy (52%).

• In patients whose tumors did not show high levels of MET, the ORR was 9%.

• Savolitinib, marketed in China under Orpathys, is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) jointly developed and commercialized by AstraZeneca and HUTCHMED (China) Ltd (NASDAQ: HCM).

• The safety profile of Tagrisso plus savolitinib was consistent with the known profiles of the combination and each treatment alone. No new safety signals were identified.

• The global SAFFRON Phase 3 trial will further assess the Tagrisso plus savolitinib combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following Tagrisso.

• Price Action: AZN shares are down 0.44% at $65.74 during the premarket session on the last check Monday.

See more from Benzinga

• Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs

• Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.